"Because of the SmokeScreen® array, we have the ability to reveal genetic information previously hidden in NIDA's samples. We have great confidence in SmokeScreen® ‒ it is a validated platform that will become a crucial tool in advancing addiction research and moving the field towards personalized treatment."

— Dr. Andrew Brooks, RUCDR Infinite Biologics’ Chief Operating Officer and Director of Technology Development

“We are excited to be part of BioRealm’s vision of improving human health by providing insight into the genetics of tobacco-related illness. It was a pleasure to work with BioRealm’s team of dedicated scientists to co-develop this cutting-edge technology.”

— Dr. Frank R. Witney, President and Chief Executive Officer of Affymetrix